Matrix-Metalloproteinases in Head and Neck Carcinoma–Cancer Genome Atlas Analysis and Fluorescence Imaging in Mice

Abstract

Objective

(1) Obtain matrix-metalloproteinase (MMP) expression profiles for head and neck squamous cell carcinoma (HNSCC) specimens from the Cancer Genomic Atlas (TCGA). (2) Demonstrate HNSCC imaging using MMP-cleavable, fluorescently labeled ratiometric activatable cell-penetrating peptide (RACPP).

Study Design

Retrospective human cohort study; prospective animal study.

Setting

Translational research laboratory.

Subjects and Methods

Patient clinical data and mRNA expression levels of MMP genes were downloaded from TCGA data portal. RACPP provides complementary ratiometric fluorescent contrast (increased Cy5 and decreased Cy7 intensities) when cleaved by MMP2/9. HNSCC–tumor bearing mice were imaged in vivo after RACPP injection. Histology was evaluated by a pathologist blinded to experimental conditions. Zymography confirmed MMP-2/9 activity in xenografts. RACPP was applied to homogenized human HNSCC specimens, and ratiometric fluorescent signal was measured on a microplate reader for ex vivo analysis.

Results

Expression of multiple MMPs including MMP2/9 is greater in patient HNSCC tumors than matched control tissue. In patients with human papilloma virus positive (HPV+) tumors, higher MMP2 and MMP14 expression correlates with worse 5-year survival. Orthotopic tongue HNSCC xenografts showed excellent ratiometric fluorescent labeling with MMP2/9-cleavable RACPP (sensitivity = 95.4%, specificity = 95.0%). Fluorescence ratios were greater in areas of higher tumor burden (P < .03), which is useful for intraoperative margin assessment. Ex vivo, human HNSCC specimens showed greater cleavage of RACPP when compared to control tissue (P = .009).

Conclusions

Human HNSCC tumors show increased mRNA expression of multiple MMPs including MMP2/9. We used RACPP, a ratiometric fluorescence assay of MMP2/9 activity, to show improved occult tumor identification and margin clearance. Ex vivo assays using RACPP in biopsy specimens may identify patients who will benefit from intraoperative RACPP use.

Keywords

head and neck squamous cell carcinoma fluorescence imaging the Cancer Genomic Atlas human papilloma virus

Get full access to this article

View all access options for this article.

References

Ferlay

Shin

Bray

Forman

Mathers

Parkin

. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.

D’Souza

Kreimer

Viscidi

. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356:1944-1956.

Shin

Khuri

. Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck. 2013;35:443-453.

Uloza

Liutkevicius

Pangonyte

Saferis

Lesauskaite

. Expression of matrix metalloproteinases (MMP-2 and MMP-9) in recurrent respiratory papillomas and laryngeal carcinoma: clinical and morphological parallels. Eur Arch Otorhinolaryngol. 2011;268:871-878.

Wittekindt

Jovanovic

Guntinas-Lichius

. Expression of matrix metalloproteinase-9 (MMP-9) and blood vessel density in laryngeal squamous cell carcinomas. Acta Otolaryngol. 2011;131:101-106.

Liu

Zeng

Hou

Chen

. Overexpression of MMP-2 in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Otolaryngol Head Neck Surg. 2005;132:395-400.

Mallis

Teymoortash

Mastronikolis

Werner

Papadas

. MMP-2 expression in 102 patients with glottic laryngeal cancer. Eur Arch Otorhinolaryngol. 2012;269:639-642.

Zhou

Gao

Johnson

Gao

. Immunoexpression of matrix metalloproteinase-2 and matrix metalloproteinase-9 in the metastasis of squamous cell carcinoma of the human tongue. Aust Dent J. 2010;55:385-389.

Chaudhary

Singh

Bharti

. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck. J Biomed Sci. 2010;17:10.

10.

Olson

Aguilera

Jiang

. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol (Camb). 2009;1:382-393.

11.

Aguilera

Olson

Timmers

Jiang

Tsien

. Systemic in vivo distribution of activatable cell penetrating peptides is superior to cell penetrating peptides. Integr Biol. 2009;1:371-381.

12.

Savariar

Felsen

Nashi

. Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides. Cancer Res. 2013;73:855-864.

13.

Nguyen

Olson

Aguilera

. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci U S A. 2010;107(9):4317-4322.

14.

Haque

Contreras

McNicoll

Eckberg

Petitti

. Surgical margins and survival after head and neck cancer surger. BMC Ear Nose Throat Disord. 2006;16:2.

15.

Singletary

. Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. Am J Surg. 2002;184:383-393.

16.

Nagtegaal

Quirke

. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin On. 2008;26:303-312.

17.

Meric

Mirza

Vlastos

. Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer. 2003;97:926-933.

18.

Snijder

de la Riviere

Elbers

van den Bosch

. Survival in resected stage I lung cancer with residual tumor at the bronchial resection margin. Ann Thorac Surg. 1998;65:212-216.

19.

Dotan

Kavanagh

Yossepowitch

. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. J Urol. 2007;178:2308-2312.

20.

Wieder

Soloway

. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol. 1998;160:299-315.

21.

Gross

Orosco

Shen

. A prognostic model of head and neck cancer ties TP53 mutation to 3p loss. Nature Genetics. In Press.

22.

Toth

Sohail

Fridman

. Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography. Methods Mol Biol. 2012;878:121-135.

23.

Rampersaud

Sun

Moul

Madden

Freedland

. Percent tumor involvement and risk of biochemical progression after radical prostatectomy. J Urol. 2008;180:571-576.

24.

Thompson

III Salem

Chang

. Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: a tale of two methods. World J Urol. 2011;29:15-20.

25.

Xia

Akers

Eisen

Seltzer

. Comparison of cleavage site specificity of gelatinases A and B using collagenous peptides. Biochim Biophys Acta. 1996;1293:259-266.

26.

Maruyama

Yasui

Ishikawa-Fujiwara

. Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population. Cancer Sci. 2014;105(4):409-417.

27.

Sivars

Nasman

Tertipis

. Human papillomavirus and p53 expression in cancer of unknown primary in the head and neck region in relation to clinical outcome. Cancer Med. 2014;3:376-384.

28.

Kuniyasu

Troncoso

Johnston

. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res. 2000;6:2295-2308.

29.

Kohrt

Nouri

Nowels

Johnson

Holmes

Lee

. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med. 2005;2:e284.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.16 MB